Johanna Friedl-Naderer, Chief Commercial Officer at Dyne Therapeutics, sold DYN on Sep 8, 2026
Data as of Oct 16
▼ SELL$3.5K185 shares at $18.88Johanna Friedl-Naderer Chief Commercial OfficerDYN Dyne Therapeutics, Inc.
- Traded
- Sep 8, 2026
- Disclosed
- Sep 8, 2026
- Filed
- The same day
Form 4s are due within two business days.
Official filing (SEC Form 4) ↗
The price around the disclosure
DYN since disclosure
−29.8%
after the sale
Similar stocks (XLV) since disclosure
+5.7%
XLV — its sector index fund
Change in closing price from Sep 8, 2026 (the first trading day on or after disclosure) to Oct 16, 2026. Dividends excluded. Not a return anyone earned.
Our take
None of our tested rules fired on this trade.
Other trades in the same filing
- ▼ SELLJohanna Friedl-Naderer Chief Commercial OfficerDYN Dyne Therapeutics, Inc.$21.9Kdisclosed Sep 8 · filed 4 days after the trade